Virex Health

Name

Virex Health

Website

https://virexhealth.com

Company type

Private

Founded year

2020

Headcount range

1–10 employees

Short description

Virex Health is a privately held, early-stage biotechnology company founded in 2020 in Wellesley, Massachusetts, developing diagnostic testing capabilities intended for use in homes, workplaces, schools, and public spaces globally.

Ownership category

akta.pro rank

Product category

Diagnostic Testing

NAICS

Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

At-Home Lab Testing & Diagnostics-Integrated Virtual Care (HLALAAAE)

Keywords

• Diagnostic testing solutions
• Biotechnology testing
• Infectious disease testing
• Biosensing technology
• Rapid testing platforms

Headquarters

HQ city

Wellesley

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Virex Health is a biotechnology firm founded in 2020 that develops solutions enabling widespread diagnostic testing across life, homes, workplaces, schools, and public spaces globally. The company's offerings are designed to support broad-based testing deployment in institutional and community settings.

Differentiator

Problem solved

Functional benefit

Products and services

• Widespread Testing Solutions

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Ellume: Ellume develops at-home digital immunoassay diagnostics marketed direct-to-consumer for respiratory health and other indications. Its combination of consumer brand, at-home format, and multi-test menu aligns closely with Virex's setting-agnostic testing vision.
• 23andMe: 23andMe pioneered direct-to-consumer at-home sample collection and testing at scale. As a DTC diagnostics brand with a home-based testing model, it is broadly comparable in go-to-market approach even though its analyte (DNA) differs from infectious disease.
• Everlywell: Everlywell operates a direct-to-consumer at-home testing marketplace spanning infectious disease, women's health, and wellness panels. Its consumer channel and multi-indication menu overlap with Virex's at-home testing narrative.
• Lucira Health: Lucira (acquired by Pfizer) commercialized a single-use at-home PCR molecular diagnostic for COVID-19 and flu. Its consumer-facing, take-anywhere format directly parallels Virex's promise of access to testing in homes and public spaces.
• Cue Health: Cue Health developed and commercialized a molecular at-home diagnostic platform (initially COVID-19) deployable in homes, schools, and workplaces. It is the closest large-scale analog to Virex's stated mission of enabling widespread decentralized testing across settings.
• Detect: Detect builds a PCR-grade at-home molecular diagnostic platform. As an emerging molecular diagnostics challenger aimed directly at decentralized settings, it competes for the same technical and commercial wedge Virex appears to target.

Broad incumbents

• Abbott Diagnostics: Abbott operates a broad diagnostic portfolio including the BinaxNOW at-home and rapid point-of-care tests. As a large incumbent with established retail, clinical, and at-home channels, it defines the competitive landscape Virex must enter.
• bioMérieux / BioFire Diagnostics: bioMérieux (through BioFire) dominates syndromic molecular diagnostics for clinical settings. While more centralized than Virex's vision, it represents the established diagnostics incumbent whose menu and channel Virex would need to compete with or complement.
• QuidelOrtho: QuidelOrtho is a major rapid diagnostics manufacturer (QuickVue, Sofia, Triage) supplying hospitals, physician offices, and increasingly consumer/direct channels. It is the broad incumbent reference point for decentralized testing economics.

Emerging players

• Talis Biomedical: Talis developed a point-of-care molecular diagnostic platform (initially for influenza/RSV/STI) with emphasis on decentralized clinical use. It overlaps with Virex on molecular diagnostics and decentralized deployment but is geared to clinical settings.

Market position

Customer concentration

• LinkedInlinkedin.com/company/virexhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virex Health